Canaccord Biotech Meeting Takeaways Part II: NPSP, ONXX, TSRX, & VICL
Tweet
Share
E-mailGet Alerts NPSP Hot Sheet
Price: $45.97 --0%
Rating Summary:
8 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Biotech Meeting Takeaways Part II
Analyst, George Farmer, held a series of meeting with biotech management in San Francisco. Some highlights points from the meetings include:
NPS Pharmaceuticals (Nasdaq: NPSP)(BUY): NPSP management expects GATTEX NDA acceptance by mid-February. Consistent with company sentiment, we remain confident that FDA will accept the NDA for review, as the regulatory filing has received input from experienced regulatory consultants.
ONXX Pharmaceuticals (Nasdaq: ONXX)(BUY): We sense that management is resigned to the high possibility that the recently accepted NDA for carfilzomib marketing authorization in relapsed/refractory multiple myeloma will receive an Approvable Letter by a July PDUFA date.
Trius Therapeutics (Nasdaq: TSRX)(BUY): We believe that positive results from the Phase III ‘112 trial evaluating tedizolid vs. standard-of-care linezolid significantly de-risk the outcome of the Phase III ‘113 trial evaluating IV-to-oral dosing transition.
Vical (Nasdaq: VICL)(BUY): Breakfast conversation with management indicates that the timeline for data read-out of the Phase III trial evaluating lead asset Allovectin-7 vs. chemotherapy for treatment of metastatic melanoma has been modified from Q2 to June.
Analyst, George Farmer, held a series of meeting with biotech management in San Francisco. Some highlights points from the meetings include:
NPS Pharmaceuticals (Nasdaq: NPSP)(BUY): NPSP management expects GATTEX NDA acceptance by mid-February. Consistent with company sentiment, we remain confident that FDA will accept the NDA for review, as the regulatory filing has received input from experienced regulatory consultants.
ONXX Pharmaceuticals (Nasdaq: ONXX)(BUY): We sense that management is resigned to the high possibility that the recently accepted NDA for carfilzomib marketing authorization in relapsed/refractory multiple myeloma will receive an Approvable Letter by a July PDUFA date.
Trius Therapeutics (Nasdaq: TSRX)(BUY): We believe that positive results from the Phase III ‘112 trial evaluating tedizolid vs. standard-of-care linezolid significantly de-risk the outcome of the Phase III ‘113 trial evaluating IV-to-oral dosing transition.
Vical (Nasdaq: VICL)(BUY): Breakfast conversation with management indicates that the timeline for data read-out of the Phase III trial evaluating lead asset Allovectin-7 vs. chemotherapy for treatment of metastatic melanoma has been modified from Q2 to June.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
- Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
